STOCK TITAN

Kezar Life Sciences Inc - KZR STOCK NEWS

Welcome to our dedicated news page for Kezar Life Sciences (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kezar Life Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kezar Life Sciences's position in the market.

Rhea-AI Summary
Kezar Life Sciences, Inc. (Nasdaq: KZR) will participate in three upcoming investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
conferences
-
Rhea-AI Summary
Kezar Life Sciences, Inc. (KZR) reported financial results for the second quarter of 2023, with $236.6 million in cash, and provided updates on its clinical trials for zetomipzomib in lupus nephritis and autoimmune hepatitis, as well as the dose escalation study for KZR-261.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.34%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
conferences
Rhea-AI Summary
Kezar Life Sciences reports financial results for Q1 2023 and provides a business update. PALIZADE Phase 2b trial for zetomipzomib in lupus nephritis on track to initiate in H1 2023. KZR-261 dose escalation study progressing, dose expansion study expected in H2 2023. Cash and marketable securities totaled $257.7 million as of March 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.36%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.99%
Tags
none
Kezar Life Sciences Inc

Nasdaq:KZR

KZR Rankings

KZR Stock Data

65.74M
52.50M
14.81%
67.98%
4.37%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
South San Francisco

About KZR

kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.